Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Deafness × Acetylcysteine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Peripheral Nervous System Diseases 1 Ovarian Neoplasms 1 Myeloproliferative Disorders 1 Hearing Loss, Sensorineural 1 Hearing Loss 1 Ear Diseases 1 Deafness 1 Cognitive Dysfunction 1 Chemotherapy-Related Cognitive Impairment 1

Interventions

Acetylcysteine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04291209 2023-09-06

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Sunnybrook Health Sciences Centre

Phase 1/2 Unknown

Deafness, Ear Diseases, Hearing Loss, Sensorineural, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon ⚡